<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7152899\results\search\drugs\results.xml">
  <result pre="of therapy with interferon and no additional benefit from concomitant" exact="tenofovir" post="therapy.19 The international societies, including the American Association for"/>
  <result pre="180 μg weekly; Peg-IFN-α-2b (PegIntron) 1.5 μg/kg weekly. NA treatment:" exact="entecavir" post="(Baraclude) 0.5 to 1 mg daily; tenofovir dipovoxil fumarate"/>
  <result pre="weekly. NA treatment: entecavir (Baraclude) 0.5 to 1 mg daily;" exact="tenofovir" post="dipovoxil fumarate (Viread) 300 mg daily; tenofovir alafenamide (Vemlidy)"/>
  <result pre="1 mg daily; tenofovir dipovoxil fumarate (Viread) 300 mg daily;" exact="tenofovir" post="alafenamide (Vemlidy) 25 mg daily. Abbreviations: ALT, alanine transaminase;"/>
  <result pre="liver tissue is needed for diagnosis. Preemptive antiviral therapy with" exact="valganciclovir" post="has been recommended for SOT recipients at risk, particularly"/>
  <result pre="is negative) who receive allografts from CMV IgG-positive donors.68 Oral" exact="valganciclovir" post="or intravenous ganciclovir may be used to treat CMV"/>
  <result pre="receive allografts from CMV IgG-positive donors.68 Oral valganciclovir or intravenous" exact="ganciclovir" post="may be used to treat CMV hepatitis depending on"/>
  <result pre="alone for hepatitis deltaN Engl J Med3644201132233121268724 19WedemeyerH.YurdaydinC.HardtkeS.Peginterferon alfa-2a plus" exact="tenofovir" post="disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo"/>
 </snippets>
</snippetsTree>
